These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 25065139)

  • 1. [Vaccines as an approach to the immunocorrection in herpetic infections].
    Barinskiĭ IF; Alimbarova LM; Lazarenko AA; Makhmudov FR; Sergeev OV
    Vopr Virusol; 2014; 59(1):5-11. PubMed ID: 25065139
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genital herpes vaccines--cause for cautious optimism.
    Haddow LJ; Mindel A
    Sex Health; 2006 Mar; 3(1):1-4. PubMed ID: 16607967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Inactivated herpes simplex virus types 1 and 2 divaccine as an agent for effective immunoprophylaxis of recurrent genital herpes].
    Barinskiĭ IF; Makhmudov FR
    Vopr Virusol; 2010; 55(1):35-40. PubMed ID: 20364670
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccines for Herpes Simplex: Recent Progress Driven by Viral and Adjuvant Immunology.
    Sandgren KJ; Truong NR; Smith JB; Bertram K; Cunningham AL
    Methods Mol Biol; 2020; 2060():31-56. PubMed ID: 31617171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The challenge of developing a herpes simplex virus 2 vaccine.
    Dropulic LK; Cohen JI
    Expert Rev Vaccines; 2012 Dec; 11(12):1429-40. PubMed ID: 23252387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Of mice and not humans: how reliable are animal models for evaluation of herpes CD8(+)-T cell-epitopes-based immunotherapeutic vaccine candidates?
    Dasgupta G; BenMohamed L
    Vaccine; 2011 Aug; 29(35):5824-36. PubMed ID: 21718746
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A killed commercial vaccine against herpes simplex viruses 1 and 2 as an immunocorrective agent in chronic herpetic infection].
    Barinskiĭ IF; Kasparov AA; Lazarenko AA; Alimbarova LM; Davydova AA; Belkina IV; Platonova AL
    Zh Mikrobiol Epidemiol Immunobiol; 1999; (6):98-102. PubMed ID: 10876868
    [No Abstract]   [Full Text] [Related]  

  • 8. Seroprevalence of HSV-1 and HSV-2 antibodies in Canadian women screened for enrolment in a herpes simplex virus vaccine trial.
    Gorfinkel IS; Aoki F; McNeil S; Dionne M; Shafran SD; Zickler P; Halperin S; Langley J; Bellamy A; Schulte J; Heineman T; Belshe R
    Int J STD AIDS; 2013 May; 24(5):345-9. PubMed ID: 23970700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protective immunity to genital herpes simplex virus type 1 and type 2 provided by self-adjuvanting lipopeptides that drive dendritic cell maturation and elicit a polarized Th1 immune response.
    Bettahi I; Zhang X; Afifi RE; BenMohamed L
    Viral Immunol; 2006; 19(2):220-36. PubMed ID: 16817765
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential prophylactic and therapeutic vaccines for HSV infections.
    Ramachandran S; Kinchington PR
    Curr Pharm Des; 2007; 13(19):1965-73. PubMed ID: 17627530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A paradigm shift: vaccine-induced antibodies as an immune correlate of protection against herpes simplex virus type 1 genital herpes.
    Awasthi S; Friedman HM
    J Infect Dis; 2014 Mar; 209(6):813-5. PubMed ID: 24285847
    [No Abstract]   [Full Text] [Related]  

  • 12. Vaccines for herpes simplex virus infections.
    Koelle DM
    Curr Opin Investig Drugs; 2006 Feb; 7(2):136-41. PubMed ID: 16499283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modelling efforts needed to advance herpes simplex virus (HSV) vaccine development: Key findings from the World Health Organization Consultation on HSV Vaccine Impact Modelling.
    Gottlieb SL; Giersing B; Boily MC; Chesson H; Looker KJ; Schiffer J; Spicknall I; Hutubessy R; Broutet N;
    Vaccine; 2019 Nov; 37(50):7336-7345. PubMed ID: 28647165
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Associations of HLA-A, HLA-B and HLA-C alleles frequency with prevalence of herpes simplex virus infections and diseases across global populations: implication for the development of an universal CD8+ T-cell epitope-based vaccine.
    Samandary S; Kridane-Miledi H; Sandoval JS; Choudhury Z; Langa-Vives F; Spencer D; Chentoufi AA; Lemonnier FA; BenMohamed L
    Hum Immunol; 2014 Aug; 75(8):715-29. PubMed ID: 24798939
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current status and prospects for development of an HSV vaccine.
    Johnston C; Koelle DM; Wald A
    Vaccine; 2014 Mar; 32(14):1553-60. PubMed ID: 24016811
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of different forms of herpes simplex replication-defective mutant viruses as vaccines in a mouse model of HSV-2 genital infection.
    Da Costa XJ; Morrison LA; Knipe DM
    Virology; 2001 Sep; 288(2):256-63. PubMed ID: 11601897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.
    Hoshino Y; Dalai SK; Wang K; Pesnicak L; Lau TY; Knipe DM; Cohen JI; Straus SE
    J Virol; 2005 Jan; 79(1):410-8. PubMed ID: 15596834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Vitaherpavac is the first Russian herpes simplex virus vaccine obtained on the Vero B continuous cell line].
    Barkhaleva OA; Ladyzhenskaia IP; Vorob'eva MS; Shalunova NV; Podcherniaeva RIa; Mikhaĭlova GR; Khorosheva TV; Barinskiĭ IF
    Vopr Virusol; 2009; 54(5):33-7. PubMed ID: 19882901
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Herpes simplex virus type 2 vaccines: new ground for optimism?
    Aurelian L
    Clin Diagn Lab Immunol; 2004 May; 11(3):437-45. PubMed ID: 15138167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunology. Painful failure of promising genital herpes vaccine.
    Cohen J
    Science; 2010 Oct; 330(6002):304. PubMed ID: 20947733
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.